BCR and chronic myelogenous leukemia, BCR-ABL1 positive: A decrease in phosphorylated STAT3 and an undetectable BCR-AB1 transcript were observed after treatment with ruxolitinib (INCB18424), a JAK inhibitor, in combination with the TKI, nilotinib, in CML patients in a phase I trial (NCT01702064) [10].